General ENT News

ENT

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Kaliner MA et al. - No significant between-treatment differences were determined for the average 2-week percent changes from baseline for congestion, runny nose, sneezing, itchy nose, and ocular symptoms, although olopatadine had a faster onset of action for reducing all symptoms. Both treatments were safe and well tolerated. Olopatadine and fluticasone nasal sprays both reduced nasal and ocular SAR symptoms with no significant between-treatment differences except for a faster and greater onset of action with olopatadine.


Today in Allergy...keeping you current

Oral Allergy Syndrome
Allergology International, 10/30/09

Montelukast in the treatment of asthma and beyond
Expert Review of Clinical Immunology, 11/23/09

Clinical Studies of Combination Montelukast and Loratadine in Patients with Seasonal Allergic Rhinitis
Journal of Asthma, 11/11/09

Today in Nose...keeping you current

Role of adenoids and adenoiditis in children with allergy and otitis media
Current Allergy and Asthma Reports, 10/22/09

Montelukast in the treatment of asthma and beyond
Expert Review of Clinical Immunology, 11/23/09

Saline Nasal Irrigation for Upper Respiratory Conditions
American Family Physician, 11/12/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address